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Abstract: BACKGROUND The PainFree Smart Shock Technology (SST) study showed a low implantable
cardioverter-defibrillator (ICD) inappropriate shock rate. However, the majority of patients were from
Western countries with patient characteristics different from those in Japan. ICD shock rates using
the novel SST algorithms in Japanese patients are still unknown. METHODS All 2,770 patients in the
PainFree SST study (Japan [JPN]: N = 181, other geographies [OJPN]: N = 2,589) were included in this
analysis. RESULTS Japanese patients had higher average left ventricular ejection fraction (P < 0.0001),
higher prevalence of secondary prevention indications (P < 0.0001), nonischemic cardiomyopathy (P <
0.0001), and permanent atrial fibrillation (P < 0.0001). The appropriate shock rate at 12 months was
not different between JPN and OJPN: 6.4% and 6.3%, respectively (P = 0.95). The inappropriate shock
rate at 12 months was significantly higher in Japanese patients (2.9% vs 1.7%, P = 0.017). However,
after propensity score matching to adjust for the difference in baseline characteristics, the difference in
inappropriate shock rate was not statistically significant (P = 0.51). CONCLUSIONS There was no
difference in the appropriate shock rate between Japan and other geographies. The inappropriate shock
rate in Japan was low, although it was slightly higher compared to other geographies due to baseline
characteristics, including a higher prevalence of permanent AF. There was not a statistically significant
difference after adjusting for baseline characteristics.
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Abstract (250 words) 
Background: The PainFree Smart Shock Technology (SST) study showed a low ICD 
inappropriate shock rate. However, the majority of patients were from Western countries 
with patient characteristics different from those in Japan. ICD shock rates using the novel 
SST algorithms in Japanese patients are still unknown. 
Methods: All 2,770 patients in the PainFree SST study (Japan [JPN]: N = 181, other 
geographies [OJPN]: N = 2,589) were included in this analysis.  
Results: Japanese patients had higher average LVEF (P < 0.0001), higher prevalence of 
secondary prevention indications (P < 0.0001), non-ischemic cardiomyopathy (P < 0.0001), 
and permanent AF (P < 0.0001). The appropriate shock rate at 12 months was not different 
between JPN and OJPN: 6.4% and 6.3%, respectively (P = 0.95). The inappropriate shock rate 
at 12 months was significantly higher in Japanese patients (2.9% vs. 1.7%, P = 0.017). 
However, after propensity score matching to adjust for the difference in baseline 
characteristics, the difference in inappropriate shock rate was not statistically significant (P 
= 0.51). 
Conclusions: There was no difference in the appropriate shock rate between Japan and 
other geographies. The inappropriate shock rate in Japan was low, although it was slightly 
higher compared to other geographies due to baseline characteristics including a higher 
prevalence of permanent AF. There was not a statistically significant difference after 
adjusting for baseline characteristics.  
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Introduction:  
A number of large-scale clinical studies have shown that implantable cardioverter-
defibrillators (ICDs) are one of the most effective therapies to prevent sudden cardiac death 
regardless of the underlying cardiac condition (ischemic or non-ischemic) or the intended 
use (primary or secondary prevention).1-3 Although appropriate ICD shocks improve survival, 
shocks may cause anxiety and psychological distress and increase mortality.4-7 The PainFree 
SST clinical study was conducted to evaluate the efficacy of a novel suite of detection 
algorithms designated as “Smart Shock Technology”. Use of this technology combined with 
modern programming led to a very low inappropriate shock rate in the range of 1.5% per 
year for dual-chamber ICDs.8 Nevertheless, this clinical study was conducted mainly in 
Western countries and did not thoroughly reflect the patient background of the population 
from eastern Asia including Japan. It is known that patient baseline characteristics are 
different between Western countries and Japan.9-10 However, it is unknown if these 
differences lead to different outcomes including the occurrence of inappropriate shocks. In 
this study, ICD shock rates from Japanese and non-Japanese patients who were enrolled in 
the PainFree SST study were compared to elucidate the effectiveness of the discrimination 
algorithms in the Japanese population. The impact of differences in patient baseline 
characteristics on inappropriate shock rates was assessed in order to inform ICD patient 
management. 
Methods:  
Study design: 
The methods and primary results of the PainFree SST study have been published.8 In brief, 
the study was a prospective, multi-center, global clinical study conducted mainly in the US, 
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Europe, Middle East, Asia, and Japan. The study enrolled patients who had a clinical 
indication for an ICD for either primary or secondary prevention of sudden cardiac death 
and intended to receive a single-chamber (SC) or dual/triple-chamber (DC) Protecta® device 
(Medtronic plc, Minneapolis, MN). The primary endpoint was the percentage of patients 
receiving at least 1 inappropriate shock at 12 months. Secondary endpoints included the 
percentage of patients receiving any inappropriate device therapy (i.e., shocks and/or anti-
tachycardia pacing (ATP)) at 12 months, the causes of inappropriate shocks, the incidence of 
appropriate device therapy, and evaluation of any under- treatment of ventricular 
arrhythmias. All patients were followed until study closure but not less than 1 year. Total 
study duration was 4 years, from September 2009 until September 2013.  
Device programming was mostly “out of box” settings. Ventricular Fibrillation (VF) 
detection zone was programmed with a detection interval of 320 ms. Ventricular 
Tachycardia (VT) detection zone was recommended to be programmed OFF in primary 
prevention patients and left to physician discretion in secondary prevention patients. 
Discrimination algorithms were programmed ON, per the nominal “out of box” settings of 
the device. Supra-ventricular tachycardia (SVT) discrimination algorithms were active for 
median ventricular intervals > 260ms. In primary prevention patients, the VF number of 
intervals to detect (NID) was programmed to 30/40, which is clinically proven to safely 
reduce shocks.11 Secondary prevention patients were randomized 1:1 to either VF NID 
30/40 or 18/24.12 Further details are described in the design paper.13  
The PainFree SST study was approved by the local institutional review boards and 
informed consent was obtained from each patient prior to any study procedures taking 
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place. Episodes were adjudicated by an episode review committee comprised of 9 
independent physicians who were not study investigators. 
In this substudy, we compared subsets of PainFree SST study patients from Japan 
(JPN) and from other geographies (OJPN) to evaluate appropriate and inappropriate ICD 
shock rates in each group.  
Statistical Methods: 
Baseline characteristics and programming parameters are summarized using percentages 
for categorical variables and mean and standard deviation for continuous variables. Fisher 
exact test and t-test were used for frequency and continuous outcome, respectively, 
comparing JPN and OJPN patients.  
The Kaplan-Meier method was used to estimate appropriate and inappropriate 
shock rates. Curves are presented with 95% log-scale confidence interval. The survival 
curves were compared for geographic subgroups (JPN vs. OJPN) with a log-rank test. Hazard 
ratios with their confidence interval were obtained from Cox regression. The interaction 
between geography and baseline variables was assessed by including separate baseline 
effects for JPN and OJPN patients. Given the broad inclusion criteria and regional differences 
in baseline patient characteristics, propensity score matching was applied to compare the 
inappropriate shock rate with adjusted baseline characteristics between the cohorts. 
Missing values of baseline characteristics were imputed first (multiple imputation). 
Propensity scores were calculated from a logistic regression model including the significantly 
different characteristics shown in Table 1 and averaged among the imputed data sets. 
Greedy matching was then implemented to find three OJPN patients to match one JPN 
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patient. Standardized differences were used to assess balance between JPN and matched 
OJPN patients, and a value ≤ 0.25 was considered acceptable balance. 
Results:  
Study population 
In total, 2,770 patients consisting of 181 JPN patients (144 DC and 37 SC) and 2,589 OJPN 
patients (1,875 DC and 714 SC) were included in this study. The OJPN patients were 
predominantly from Western countries (United States 33.4%, Western Europe 32.9%, 
Southern Europe 11.1%, Canada 10.2%, Other 12.4%; Table S1 in the Online Appendix) and 
were largely of white/Caucasian race (80.9%). The follow-up durations of JPN and OJPN 
patients were 21 ± 6 months and 22 ± 10 months, respectively. There were many 
differences in baseline characteristics between the groups (Table 1). Notably, Japanese 
patients had a higher average left ventricular ejection fraction (LVEF, 44% vs. 31%, P < 
0.0001), more received the ICD for secondary prevention (56% vs. 29%, P < 0.0001), fewer 
had ischemic cardiomyopathy (17% vs. 45%, P < 0.0001), more had permanent atrial 
fibrillation (AF, 19% vs. 9%, P < 0.0001), and more used antiarrhythmic drugs (40% vs. 17%, P 
< 0.0001). Permanent AF was present in 35.1% of Japanese patients implanted with SC ICDs 
(Table S2 in the Online Appendix). Propensity score matching successfully identified a sub-
group of OJPN patients comparable to the JPN patients (Table 1), as demonstrated by 
standardized differences that were all less than 0.25, except for LVEF and Inotropic agent 
use (Figure S1 in the Online Appendix). 
Device Programming 
Although the majority of patients in this study were set to VF NID 30/40, a higher 
percentage of JPN patients were set to 18/24 than OJPN (28% vs 18%, P = 0.002) due to 
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randomization of the VF NID in secondary prevention patients. In addition, fewer JPN 
patients were programmed with Sinus Tachycardia Discrimination ON (86% vs. 98%, P < 
0.0001). JPN patients were also programmed with a longer VF detection interval (307.8 ± 
14.5 vs. 303.4 ± 17.5 ms, P = 0.0001), and a longer VT detection interval (393.2 ± 43.0 vs. 
354.3 ± 30.0 ms, P <  0.0001) when VT detection was programmed ON (62% vs. 63%, P = 
0.75).  
Appropriate shock 
There was no difference in the incidence of appropriate shocks in JPN compared to OJPN, 
both overall, and when stratified by indication (Figure 1, Online Appendix Figure S2). The 
appropriate shock rates at 12 months were 6.4% and 6.3% for JPN and OJPN, respectively (P 
= 0.95) (Figure 1). In addition, there was no difference in the incidence of appropriate 
shocks across other geographies (Online Appendix Figure S3). 
Inappropriate shock 
There was a higher incidence of inappropriate shocks in JPN compared to OJPN (at 12 
months, 2.9% and 1.7%, respectively, P = 0.017, Hazard Ratio = 2.22) (Figure 2A). The 
incidence rate of inappropriate therapy (shock and ATP) after one year post-implant was 
4.7% in JPN. Across OJPN geographies, the inappropriate shock rate was comparable except 
for a higher rate in Saudi Arabia (Online Appendix Figure S4). 
In JPN patients, there was a difference in the inappropriate shock rate between 
patients with SC and DC devices (P=0.01) (Figure 2B); however, there was no difference in 
the inappropriate shock rate when comparing JPN and OJPN patients with DC devices (P = 
0.21). Additionally, more JPN patients with inappropriate shocks had a history of permanent 
AF, compared to JPN patients without inappropriate shocks (P = 0.025) and OJPN patients 
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with inappropriate shocks (P = 0.006, Online Appendix Table S3). The most frequent 
adjudicated cause of an inappropriate shock for both JPN and OJPN patients was AF or atrial 
flutter (Table 2). The inappropriate shock rate was significantly higher for Japanese patients 
with permanent AF compared to OJPN patients with permanent AF (P = 0.004) but similar in 
patients without permanent AF (P = 0.52) (Figure 2C). After propensity matching to adjust 
for differences in baseline characteristics, there was no statistical difference in the 
inappropriate shock rate between JPN and OJPN (P = 0.51, Figure 3). 
Discussion:  
In a sub-analysis of JPN patients and OJPN patients from the PainFree SST study, we found 
the appropriate shock rate was comparable between groups. The inappropriate shock rate 
was higher in JPN than that of OJPN; however, after adjusting for differences in baseline 
characteristics, there was no longer a difference in the rate of inappropriate shocks. To our 
knowledge, this is the first report comparing the rates of appropriate and inappropriate 
shocks between JPN and OJPN using patients from a single study. 
Appropriate shock rate 
Although it was anticipated that the appropriate shock rate would be higher in the Japanese 
population since there were more patients receiving the device for secondary prevention,14 
results from this report showed that the incidence of appropriate shock was similar 
between JPN and OJPN (Figure 1). This may be related to the fact that the Japanese 
population in this study is comprised of patients with relatively good cardiac function, lower 
incidence of myocardial infarction, and fewer patients with ischemic cardiomyopathy, all of 
which have been reported to predict incidence of appropriate therapy (Online Appendix 
Figure S2).15 Further research is warranted. 
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Inappropriate shock rate 
Results from this sub-analysis of the PainFree SST study demonstrated that the 
inappropriate shock rate was significantly higher in Japanese patients. This could be 
explained by the difference in patient baseline characteristics as demonstrated by the 
propensity adjusted analysis. As seen in Table 1, many parameters are significantly different 
between JPN and OJPN, including the prevalence rates of Brugada syndrome and congenital 
long QT syndrome being significantly higher and the rate of ischemic cardiomyopathy being 
lower in JPN. It is noteworthy that prevalence of permanent AF, a well-known cause for 
inappropriate shocks, is high, especially in patients implanted with SC ICDs (35.1%). In Japan, 
SC ICDs are predominantly chosen for patients with permanent AF as atrial pacing and 
sensing are not necessary in this population. When SC ICDs are implanted in patients with 
permanent AF, advanced SVT discrimination algorithms such as PR logic® cannot be utilized; 
thus, the diagnosis must rely on the rate, stability criteria, and morphology, which may have 
less specificity and result in more inappropriate shocks.8 In the present study, JPN patients 
only demonstrated a higher inappropriate shock rate in patients implanted with SC ICDs and 
not in those with DC ICDs. Additionally, since it has been reported that a ventricular rate 
above 90 - 110 bpm during AF increases the risk of inappropriate shock,16-17 rate control 
during AF may also play a crucial role. In the ECOST trial,18 the number of inappropriate 
shocks decreased by utilizing remote monitoring and diagnostic features of the ICD, 
facilitating early intervention to treat the conditions which may lead to inappropriate shocks. 
As such, rate control by utilizing remote monitoring could be an effective method to prevent 
inappropriate shocks.  
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Since secondary prevention use is the most common indication in Japan, the VT zone 
was programmed ON in many patients, with significantly longer detection interval than for 
OJPN, which may have increased the possibility of inappropriate shock. However, previous 
results from the PainFree SST study have shown that setting the VT zone ON did not affect 
the incidence rate of inappropriate shock. Additionally, the rate was similar among primary 
and secondary prevention patients.8 
As differences in patient backgrounds between patients in JPN and OJPN may have 
contributed to the difference in inappropriate shock rate, a propensity analysis was 
performed. After propensity matching, the incidence rate of inappropriate shock was 
comparably low in JPN and OJPN. Ueda et al. have reported that the inappropriate shock 
rates in patients with a SC ICD or DC ICD were 19% or 12%, respectively, during 4.5 years of 
follow-up; however, the study excluded patients with a history of permanent AF.19 Results 
from the largest-scale prospective registry study in Japan (Nippon Storm) have reported that 
the incidence rate of inappropriate therapy (shock and ATP) after one year post-implant was 
6.7%,19 which was higher than the 4.7% reported in this study. The registry period of Nippon 
Storm was almost the same as PainFree SST, and the patient backgrounds were similar; 
however, the implanted devices were different. Therefore, the difference in the incidence 
rate of inappropriate shock between these studies could support the effectiveness of Smart 
Shock Technology. The results of this study may help guide Japanese physicians in both the 
choice and programming of ICD devices. Furthermore, knowledge of regional differences in 
patient characteristics and current practice regarding device therapy makes it possible to 
develop ICD device algorithms and programming strategies that are tailored to the region. 
Limitations:  
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Some limitations should be considered in interpreting the results of this study. The results 
were analyzed retrospectively and the number of Japanese patients was small. Study 
enrollment began later in Japan, thus the follow-up duration in Japanese patients is shorter; 
however, comparative results cover only the first 24 months post implant, which is within 
the Japanese patient follow-up duration. Propensity score matching analysis was conducted 
using only the baseline data collected in the PainFree SST study and does not take into 
account data not collected in the study that may impact the results. The matching reduced, 
but did not fully balance, the difference between Japanese and OJPN patients on LVEF and 
the use of inotropic agents.  
Conclusion:  
This is the first reported comparison of ICD shock rates between Japan and other 
geographies within the same study cohort. There was no difference in the appropriate shock 
rate between these two populations. The inappropriate shock rate in Japan was low, 
although it was slightly higher compared to other geographies, this was associated with 
differences in baseline characteristics including a higher prevalence of permanent AF and 
more use of single chamber ICDs in patients with permanent AF in Japan. The inappropriate 
shock rates were comparable between the geographies after adjusting for differences in 
baseline characteristics.   
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Figure Legends 
 
Figure 1. Appropriate shocks in Japan (JPN) and other geographies (OJPN). Follow-up 
duration is shorter in Japan as the study started earlier in Europe than Japan.  
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Figure 2A. Inappropriate shocks in Japan (JPN) and other geographies (OJPN). 
Figure 2B. Inappropriate shocks by device type (single chamber (SC) and dual/triple 
chamber (DC)) in Japan (JPN) and other geographies (OJPN).  
Figure 2C. Inappropriate shocks in patients with or without permanent atrial fibrillation (AF) 
in Japan (JPN) and other geographies (OJPN).  
 
Figure 3. Inappropriate shocks in Japanese patients (JPN) and propensity-matched patients 
from other geographies (Matched). 
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Table 1. Baseline Characteristics 
Patient Characteristics 
Japan 
(N = 181) 
Other 
geographies 
(N = 2,589) 
Matched  
patients in 
Other 
geographies 
(N = 543) 
P-value* 
Gender, Male (%) 76.2 79.6 76.1 0.25 
Age (years) 65.5 ± 12.1 64.8 ± 12.3 65.3 ± 13.3 0.49 
LVEF (%) 43.9 ± 18.3 31.4 ± 12.3 38.2 ± 15.5 <0.0001 
QRS (ms) 124.6 ± 33.9 126.0 ± 33.0 125.7 ± 33.4 0.58 
Indication, Primary (%) 43.6 71.0 54.1% <0.0001 
NYHA class I/II/III/IV (%) 25/41/19/1 14/40/32/1 20/43/22/1 0.001 
Brugada syndrome (%) 7.7 0.5 2.4 <0.0001 
Cardiomyopathy, ischemic (%) 17.1 45.4 24.3 <0.0001 
Congestive heart failure (%) 29.8 38.9 33.5 0.017 
Coronary artery disease (%) 19.3 47.2 23.4 <0.0001 
Hypertension (%) 26.0 54.0 35.0 <0.0001 
Myocardial infarction (%) 17.1 39.3 24.5 <0.0001 
Syncope, any (%) 32.6 14.4 22.1 <0.0001 
Valve dysfunction, any (%) 14.4 25.9 16.8 <0.001 
Coronary artery bypass graft (CABG) (%) 8.8 24.8 11.2 <0.0001 
Previous device, any (%) 34.8 33.2 36.1 0.68 
Atrial fibrillation (%) 38.1 28.9 33.9 0.011 
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  Atrial fibrillation, paroxysmal (%) 11.0 14.7 14.7 0.19 
  Atrial fibrillation, persistent (%) 7.7 5.5 4.6 0.24 
  Atrial fibrillation, permanent (%) 19.3 9.0 14.7 <0.0001 
Atrial flutter (%) 5.5 4.9 6.1 0.72 
Atrial tachycardia (%) 3.3 2.0 2.6 0.27 
Sinus bradycardia (%) 7.7 5.3 5.2 0.18 
Long Q/T syndrome (%) 4.4 0.6 1.1 <0.0001 
Ventricular fibrillation (%) 25.4 9.3 18.4 <0.0001 
Ventricular tachycardia, any (%) 51.9 34.6 46.4 <0.0001 
AV block, any (%) 17.1 14.4 14.5 0.33 
Left bundle branch block (%) 13.3 26.1 19.2 <0.0001 
Device detection (%)    0.038 
  Dual Chamber (ICD and CRT-D) 79.6 72.4 69.8  
  Single Chamber 20.4 27.6 30.2  
Beta-Blocker (%) 69.1 86.7 77.2 <0.0001 
ACE Inhibitor or ARB (%) 63.0 78.0 70.2 <0.0001 
Diuretic (%) 58.6 68.8 64.3 0.006 
Inotropic agent (%) 6.1 0.3 1.1 <0.0001 
Calcium Channel Blocker (%) 18.8 10.5 16.0 0.001 
Anti-Arrhythmic** (%) 40.3 17.2 32.6 <0.0001 
*Japan vs. Other geographies, Student’s t, Fisher exact and Cochran-Mantel-Haenszel testing. 
** Predominantly Amiodarone or Sotalol. 
ACE, Angiotensin converting enzyme; ARB, Angiotensin II receptor blocker; AV, atrio-ventricular; CRT-D, cardiac 
resynchronization therapy defibrillator; DC, dual chamber; ICD, implantable cardioverter defibrillator; LVEF, 
left ventricular ejection fraction; NYHA, New York Heart Association; SC, single chamber. 
 
  
This article is protected by copyright. All rights reserved. 
21 
 
 
Table 2. Cause of inappropriate shocks 
Cause of inappropriate 
shock, patient (%, event) 
Dual Chamber ICD/CRT-D Single Chamber ICD 
Japan 
(n = 144) 
Other 
geographies 
(N = 1838) 
Japan 
(N = 37) 
Other 
geographies 
(N = 751) 
Atrial fibrillation or atrial 
flutter  
5 (3.4%, 7) 21 (1.1%, 34) 3 (8.1%, 3) 13 (1.7%, 22) 
Other SVT 2 (1.4%, 2) 6 (0.3%, 9) 0 2 (0.3%, 2) 
Committed shock  
after appropriate therapy 
0 7 (0.4%, 7) 0 0 
Ablation procedure 0 0 0 1 (0.1%, 1) 
EGM noise 0 6 (0.3%, 21) 1 (2.7%, 1) 2 (0.3%, 2) 
T-wave oversensing 0 4 (0.2%, 4) 0 0 
Total 6 (4.2%, 9) 42 (2.3%, 75) 4 (10.8%, 4) 18 (2.4%, 27) 
One inappropriate shock originally reported as due to other SVT was adjudicated again and the cause was 
changed to EGM noise after the publication of the primary results. SVT, supraventricular tachycardia; EGM, 
electrogram. 
 
